| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Macranthoidin B does not have a defined single molecular target. Its anticancer mechanism involves the induction of reactive oxygen species (ROS) production and subsequent apoptosis in cancer cells. The compound is a triterpenoid saponin and a major bioactive component of Flos Lonicerae. Its biological activity may involve multiple cellular pathways, including oxidative stress induction and mitochondrial dysfunction. The compound's anticancer activity has been demonstrated in HCT116 colorectal cancer cells.
|
|---|---|
| ln Vitro |
In vitro, macranthoidin B has anticancer activity against HCT116 colorectal cancer cells. It increases the production of reactive oxygen species (ROS) and induces apoptosis in HCT116 cells when used at concentrations ranging from 20 to 400 μM. The compound's pro-apoptotic and ROS-inducing activities are dose-dependent. No other in vitro activities have been reported for macranthoidin B. The compound is a major bioactive saponin and has potential as an anticancer agent.
|
| ln Vivo |
In vivo, macranthoidin B is a major bioactive saponin detected in rat plasma after oral administration of saponin extracts from Flos Lonicerae. This indicates that the compound is bioavailable and reaches the systemic circulation following oral administration. However, specific in vivo efficacy studies have not been reported. No animal studies have evaluated its anticancer efficacy in xenograft models or other disease models. Further studies are needed to evaluate its therapeutic potential in vivo.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for macranthoidin B have not been extensively developed or reported. The compound's primary reported activity is ROS induction and apoptosis in cancer cells. These effects are typically assessed in cell-based assays rather than in direct enzyme or receptor binding studies. Further studies are needed to identify the specific molecular targets and binding affinities of macranthoidin B.
|
| Cell Assay |
In vitro cell-based assays for macranthoidin B typically employ HCT116 colorectal cancer cells. Cells are cultured in appropriate medium (e.g., McCoy's 5A or DMEM supplemented with fetal bovine serum) and treated with various concentrations of the compound (20-400 μM) for 24-48 hours. ROS production is measured using fluorescent probes such as DCFH-DA. Apoptosis is evaluated by Annexin V/PI staining and flow cytometry, as well as by detection of caspase activation and mitochondrial membrane potential loss. Cell viability is assessed by MTT or SRB assays.
|
| Animal Protocol |
In vivo animal studies with macranthoidin B have not been extensively reported. The compound has been detected in rat plasma after oral administration of Flos Lonicerae saponin extracts, indicating that it is bioavailable. However, no specific efficacy studies have been conducted in animal models. Future studies may involve administration of macranthoidin B in rodent xenograft models to evaluate its anticancer efficacy. Currently, limited in vivo data are available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of macranthoidin B have been partially characterized. The compound is detectable in rat plasma after oral administration of saponin extracts from Flos Lonicerae, indicating that it is absorbed from the gastrointestinal tract. However, specific PK parameters such as half-life, Cₘₐₓ, Tₘₐₓ, and bioavailability have not been determined. As a triterpenoid saponin with high molecular weight (1399.52), the compound may have limited oral bioavailability. Further PK studies are needed.
|
| Toxicity/Toxicokinetics |
The toxicity profile of macranthoidin B has not been extensively characterized in preclinical studies. No acute toxicity, genotoxicity, or chronic toxicity studies have been reported. As a natural saponin, the compound may have hemolytic activity and gastrointestinal side effects at high doses. However, specific toxicology data are not available. The compound is intended for research use only and is not approved for human therapeutic applications.
|
| References | |
| Additional Infomation |
Macranthoidin B is a triterpenoid saponin.
Macranthoidin B is a research-grade triterpenoid saponin found in Lonicerae species. It has anticancer activity, with the ability to induce ROS production and apoptosis in HCT116 colorectal cancer cells at concentrations of 20-400 μM. It is a major bioactive saponin detected in rat plasma after oral administration of Flos Lonicerae extracts. The compound is not an approved therapeutic drug and has no clinical trial history. It is supplied as a white powder with purity >98%. Molecular formula: C₆₅H₁₀₆O₃₂; molecular weight: 1399.52. Synonyms include Macranthoiside I. |
| Molecular Formula |
C65H106O32
|
|---|---|
| Molecular Weight |
1399.5180
|
| Exact Mass |
1398.666
|
| CAS # |
136849-88-2
|
| PubChem CID |
71307567
|
| Appearance |
White to light brown solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Index of Refraction |
1.654
|
| LogP |
2.27
|
| Hydrogen Bond Donor Count |
19
|
| Hydrogen Bond Acceptor Count |
32
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
97
|
| Complexity |
2720
|
| Defined Atom Stereocenter Count |
38
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H](CO[C@H]2O[C@H]3CC[C@]4([C@H]([C@]3(C)CO)CC[C@@]5([C@@H]4CC=C6[C@]5(CC[C@@]7([C@H]6CC(CC7)(C)C)C(=O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O)O)C)C)C)O)O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O)O)O
|
| InChi Key |
RKINZCVTEPSBCI-ZBXZRPIVSA-N
|
| InChi Code |
InChI=1S/C65H106O32/c1-25-36(71)51(95-55-48(83)44(79)50(31(21-68)91-55)94-54-46(81)42(77)39(74)30(20-67)90-54)49(84)57(88-25)96-52-37(72)28(70)22-86-58(52)93-35-11-12-61(4)33(62(35,5)24-69)10-13-64(7)34(61)9-8-26-27-18-60(2,3)14-16-65(27,17-15-63(26,64)6)59(85)97-56-47(82)43(78)40(75)32(92-56)23-87-53-45(80)41(76)38(73)29(19-66)89-53/h8,25,27-58,66-84H,9-24H2,1-7H3/t25-,27-,28-,29+,30+,31+,32+,33+,34+,35-,36-,37-,38+,39+,40+,41-,42-,43-,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54-,55-,56-,57-,58-,61-,62-,63+,64+,65-/m0/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl] (4aS,6aR,6aS,6bR,8aR,9R,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-3-[(2S,3R,4R,5S,6S)-4-[(2S,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~71.45 mM)
DMSO : ~100 mg/mL (~71.45 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.79 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (1.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (1.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (71.45 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7145 mL | 3.5727 mL | 7.1453 mL | |
| 5 mM | 0.1429 mL | 0.7145 mL | 1.4291 mL | |
| 10 mM | 0.0715 mL | 0.3573 mL | 0.7145 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
